newsfilter
← Latest News
GlobeNewswire·

BlossomHill Therapeutics Announces Pricing of Upsized $150 Million Initial Public Offering

BLSM
  • BlossomHill Therapeutics priced its upsized initial public offering of 9,375,000 common stock shares at $16.00 per share.
  • The offering is expected to generate gross proceeds of $150.0 million before underwriting discounts, commissions, & offering expenses.
  • Underwriters have a 30-day option to purchase up to an additional 1,406,250 shares at the public offering price.
  • Shares are expected to begin trading on The Nasdaq Global Select Market on August 7, 2026, under the ticker symbol "BLSM."
  • The offering is scheduled to close on August 10, 2026, subject to customary closing conditions.
  • J.P. Morgan, Leerink Partners, & Guggenheim Securities are lead book-running managers; LifeSci Capital & H.C. Wainwright & Co. are joint book-running managers.
  • Registration statements became effective with the SEC on August 6, 2026.
  • BlossomHill Therapeutics is a clinical-stage biopharmaceutical company focused on innovative small molecule cancer medicines led by founder J. Jean Cui, Ph.D.
  • The company's lead programs include BH-30643 for EGFR-mutant NSCLC, BH-30236 for R/R AML & HR-MDS, & BH-501284 for KRAS-mutant tumors.